[DOI] [PubMed] [Google Scholar] 46.Chiolero A, Faeh D, Paccaud F, Cornuz J
Taking a closer look at Primes GLP-1 Year-2 cost-of-care findings David Lassen, vice president of pharmacy clinical services, and Marci Chodroff, vice president and medical director at Prime Therapeutics, share more about the latest GLP-1 insights from ongoing research Last week, Prime Therapeutics (Prime) released the latest data from its ongoing real-world research on glucagon-like peptide-1 (GLP-1) agonist drugs, which showed individuals who newly started the drugs for weight loss experienced an average of $4,206 higher cost of care in their second year compared to like members not taking a GLP-1 drug for obesity
Some 634,897 surgical bariatric/metabolic interventions were performed worldwide in 2016 [50]
Blackwell and the team
But with the introduction of GLP1 and dual GIP/GLP-1 agonists, both in injectables and pill form, people with obesity now have a new tool to help manage the condition
